Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
LIMN Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: June 16, 2026
Report Source: 2026 1st Quarter Report
Liminatus Pharma Inc. Stock Analysis LIMN
United States Health Care Nano Cap Report: Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
Read More Liminatus Pharma Inc (LIMN) Chart
Key Statistics of Liminatus Pharma Inc (LIMN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.11Volume
1.10MP/E Ratio (TTM)
-52 Week Range
Market Cap
11.04MAvg. Volume
3.62MDividend Yield
-Financial Metrics & Statements of Liminatus Pharma Inc (LIMN)
FAQ's for Liminatus Pharma Inc (LIMN)
- According to Musaffa’s Shariah screening methodology, Liminatus Pharma Inc (LIMN) is currently classified as HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Liminatus Pharma Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Liminatus Pharma Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Liminatus Pharma Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Liminatus Pharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Liminatus Pharma Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.